New York Senate Bill S04587

New York 2025-2026 Regular Session

• Introduced: 2/7/25
• Refer: 2/7/25

Caption

Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.

Summary

This bill amends New York’s education and public health laws to change how prescription labels may identify the dispensing and prescribing entities for mifepristone and misoprostol. For dispensing, the label may include the name or address of the dispensing health care practice instead of the dispenser’s name. For prescribing, the label must include the name or address of the prescribing health care practice at the prescriber’s request instead of the prescriber’s name. The bill also adds a new patient-notification requirement so that a prescriber must tell the patient when the label will list the practice’s name or address rather than the individual prescriber’s name. The measure is tied to a separate 2025 chapter law dealing with labeling of mifepristone, misoprostol, and their generic alternatives, and it would take effect in the same manner as that law. In practical terms, it creates an additional privacy-oriented labeling option for abortion-related medications and clarifies that the practice, rather than the individual clinician, may be identified on the label. It also imposes a disclosure duty on prescribers to ensure patients are aware of the labeling format. The bill’s impact is limited to prescription labeling rules for these two medications and the related responsibilities of prescribers, dispensers, and health care practices. It does not change eligibility for the drugs or broader abortion law, but it does modify how pharmacies and medical practices document and present prescribing information on labels. The affected parties are health care prescribers, dispensing practices, pharmacies, and patients receiving mifepristone or misoprostol. Because there are no recorded committee transcripts or votes in the provided material, there is no direct evidence of debate or formal support/opposition in the bill history here. Based on the text, the bill appears to be a technical and privacy-focused follow-up to earlier labeling legislation, and any contention would likely center on patient privacy, provider anonymity, and the handling of abortion medication prescriptions rather than on the medications’ legality itself.

Impact

The bill amends Education Law sections 6807 and 6810 and adds new Public Health Law section 280-d. It authorizes prescription labels for mifepristone and misoprostol to list the dispensing health care practice’s name or address instead of the dispenser’s name, and requires the prescribing health care practice’s name or address to be included at the prescriber’s request instead of the prescriber’s name. It also requires prescribers to notify patients when this label substitution is used. These changes affect pharmacies, prescribers, health care practices, and patients receiving these medications, while operating in tandem with a separate 2025 labeling law for mifepristone and misoprostol.

Sentiment

No committee discussion or vote record was provided, so there is no documented floor or committee sentiment to summarize. From the bill text, the measure appears to be framed as a privacy and implementation refinement to existing labeling rules, suggesting a generally administrative or supportive intent rather than a broad policy overhaul. The absence of recorded opposition in the supplied materials prevents a definitive assessment of support or controversy from legislative proceedings.

Contention

The main likely point of contention is the balance between patient privacy and transparency in prescription labeling for mifepristone and misoprostol. Supporters would likely view the bill as protecting patients and providers by allowing the practice name or address to appear instead of an individual clinician’s name, while opponents could argue that it reduces identifying information on labels or complicates accountability. The new patient-notification requirement may also reflect concern that patients should understand when identifying information on the label has been altered. No specific legislators, committees, or advocacy positions are included in the provided record.